A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-04-08

AUTHORS

Andrew Cristinacce, James G. Wright, Gregory G. Stone, Jennifer Hammond, Lynn McFadyen, Susan Raber

ABSTRACT

INTRODUCTION: This retrospective analysis compares the probability of target attainment (PTA) for ceftriaxone, levofloxacin and ceftaroline fosamil against Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae in a representative patient population with moderate-to-severe community-acquired pneumonia (CAP). METHODS: Published pharmacokinetic (PK) models for levofloxacin and ceftriaxone, and an existing model for ceftaroline, were used with standard dosage regimens for simulating individual PK data with covariates representative of patients with CAP (5000 patients/drug regimen). PTA for clinically relevant pharmacokinetic/pharmacodynamic (PK/PD) targets was calculated from steady state PK profiles for a range of minimum inhibitory concentrations (MICs). Cumulative fractions of response (CFRs) were also calculated using MIC distributions from 2012 to 2017 global surveillance data. RESULTS: Ceftaroline fosamil (600 mg q12 h) achieved > 90% PTA at all exposure targets for each pathogen at European Committee on Antimicrobial Susceptibility Testing (EUCAST)/Clinical and Laboratory Standards Institute (CLSI) susceptibility breakpoints, and CFRs were > 99%. Ceftriaxone, but not levofloxacin, achieved 100% PTA and > 90% CFR against S. pneumoniae. Both levofloxacin and ceftriaxone achieved high PTA and CFR against H. influenzae. Levofloxacin achieved PTAs < 90% at EUCAST/CLSI breakpoints and ceftriaxone achieved PTAs < 90% at MICs up to 2 mg/L against S. aureus; both agents produced generally low CFRs against S. aureus (except levofloxacin against methicillin-sensitive S. aureus), reflecting the lack of activity of these agents against methicillin-resistant S. aureus. CONCLUSION: Ceftaroline fosamil demonstrated higher overall PTA rates than levofloxacin and ceftriaxone, in particular against S. aureus. These results provide insight regarding the potential comparative efficacy of the described antibiotics for moderate-to-severe CAP. FUNDING: Pfizer. More... »

PAGES

185-198

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40121-019-0243-4

DOI

http://dx.doi.org/10.1007/s40121-019-0243-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113301252

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30963520


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Wright Dose Ltd., Altrincham, Greater Manchester, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Wright Dose Ltd., Altrincham, Greater Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cristinacce", 
        "givenName": "Andrew", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wright Dose Ltd., Altrincham, Greater Manchester, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Wright Dose Ltd., Altrincham, Greater Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wright", 
        "givenName": "James G.", 
        "id": "sg:person.013655761054.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013655761054.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, Groton, CT USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer, Groton, CT USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stone", 
        "givenName": "Gregory G.", 
        "id": "sg:person.0754245536.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754245536.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, Collegeville, PA USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer, Collegeville, PA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hammond", 
        "givenName": "Jennifer", 
        "id": "sg:person.014247722033.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014247722033.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, Sandwich, Kent, UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer, Sandwich, Kent, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McFadyen", 
        "givenName": "Lynn", 
        "id": "sg:person.01164604234.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164604234.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, San Diego, CA USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Pfizer, San Diego, CA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raber", 
        "givenName": "Susan", 
        "id": "sg:person.0727526224.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727526224.27"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1465-9921-14-44", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048350425", 
          "https://doi.org/10.1186/1465-9921-14-44"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/2047-783x-15-12-507", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004325476", 
          "https://doi.org/10.1186/2047-783x-15-12-507"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00228-011-1095-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015621133", 
          "https://doi.org/10.1007/s00228-011-1095-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-08", 
    "datePublishedReg": "2019-04-08", 
    "description": "INTRODUCTION: This retrospective analysis compares the probability of target attainment (PTA) for ceftriaxone, levofloxacin and ceftaroline fosamil against Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae in a representative patient population with moderate-to-severe community-acquired pneumonia (CAP).\nMETHODS: Published pharmacokinetic (PK) models for levofloxacin and ceftriaxone, and an existing model for ceftaroline, were used with standard dosage regimens for simulating individual PK data with covariates representative of patients with CAP (5000 patients/drug regimen). PTA for clinically relevant pharmacokinetic/pharmacodynamic (PK/PD) targets was calculated from steady state PK profiles for a range of minimum inhibitory concentrations (MICs). Cumulative fractions of response (CFRs) were also calculated using MIC distributions from 2012 to 2017 global surveillance data.\nRESULTS: Ceftaroline fosamil (600\u00a0mg q12\u00a0h) achieved >\u200990% PTA at all exposure targets for each pathogen at European Committee on Antimicrobial Susceptibility Testing (EUCAST)/Clinical and Laboratory Standards Institute (CLSI) susceptibility breakpoints, and CFRs were >\u200999%. Ceftriaxone, but not levofloxacin, achieved 100% PTA and >\u200990% CFR against S. pneumoniae. Both levofloxacin and ceftriaxone achieved high PTA and CFR against H. influenzae. Levofloxacin achieved PTAs <\u200990% at EUCAST/CLSI breakpoints and ceftriaxone achieved PTAs <\u200990% at MICs up to 2\u00a0mg/L against S.\u00a0aureus; both agents produced generally low CFRs against S. aureus (except levofloxacin against methicillin-sensitive S. aureus), reflecting the lack of activity of these agents against methicillin-resistant S. aureus.\nCONCLUSION: Ceftaroline fosamil demonstrated higher overall PTA rates than levofloxacin and ceftriaxone, in particular against S. aureus. These results provide insight regarding the potential comparative efficacy of the described antibiotics for moderate-to-severe CAP.\nFUNDING: Pfizer.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40121-019-0243-4", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1050275", 
        "issn": [
          "2193-8229", 
          "2193-6382"
        ], 
        "name": "Infectious Diseases and Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "community-acquired pneumonia", 
      "severe community-acquired pneumonia", 
      "minimum inhibitory concentration", 
      "ceftaroline fosamil", 
      "retrospective analysis", 
      "Laboratory Standards Institute susceptibility breakpoints", 
      "Community-Acquired Pneumonia", 
      "steady-state PK profile", 
      "probability of target", 
      "representative patient population", 
      "global surveillance data", 
      "antimicrobial susceptibility testing", 
      "pharmacodynamic target", 
      "target attainment", 
      "exposure targets", 
      "patient population", 
      "standard dosage", 
      "susceptibility breakpoints", 
      "CLSI breakpoints", 
      "comparative efficacy", 
      "ceftriaxone", 
      "PK data", 
      "PK profiles", 
      "low CFR", 
      "Haemophilus influenzae", 
      "Streptococcus pneumoniae", 
      "MIC distribution", 
      "fosamil", 
      "susceptibility testing", 
      "pharmacokinetic model", 
      "levofloxacin", 
      "surveillance data", 
      "higher PTA", 
      "inhibitory concentration", 
      "pneumonia", 
      "lack of activity", 
      "Staphylococcus aureus", 
      "covariates representative", 
      "cumulative fraction", 
      "influenzae", 
      "aureus", 
      "pneumoniae", 
      "European Committee", 
      "PTA", 
      "CFR", 
      "ceftaroline", 
      "patients", 
      "agents", 
      "target", 
      "efficacy", 
      "antibiotics", 
      "Pfizer", 
      "breakpoints", 
      "dosage", 
      "pathogens", 
      "population", 
      "response", 
      "data", 
      "testing", 
      "activity", 
      "Committee", 
      "comparator", 
      "rate", 
      "lack", 
      "analysis", 
      "concentration", 
      "profile", 
      "attainment", 
      "fraction", 
      "probability", 
      "results", 
      "model", 
      "PTAS", 
      "insights", 
      "representatives", 
      "range", 
      "distribution", 
      "individual PK data", 
      "state PK profiles", 
      "Standards Institute (CLSI) susceptibility breakpoints", 
      "Institute (CLSI) susceptibility breakpoints", 
      "EUCAST/CLSI breakpoints", 
      "higher overall PTA rates", 
      "overall PTA rates", 
      "PTA rates", 
      "potential comparative efficacy", 
      "Ceftaroline Fosamil Versus Comparators", 
      "Fosamil Versus Comparators", 
      "Versus Comparators"
    ], 
    "name": "A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators", 
    "pagination": "185-198", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113301252"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40121-019-0243-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30963520"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40121-019-0243-4", 
      "https://app.dimensions.ai/details/publication/pub.1113301252"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:43", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_797.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40121-019-0243-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40121-019-0243-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40121-019-0243-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40121-019-0243-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40121-019-0243-4'


 

This table displays all metadata directly associated to this object as RDF triples.

207 TRIPLES      22 PREDICATES      118 URIs      107 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40121-019-0243-4 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N038ae07836674397b0fccbc3efb6fcb2
4 schema:citation sg:pub.10.1007/s00228-011-1095-3
5 sg:pub.10.1186/1465-9921-14-44
6 sg:pub.10.1186/2047-783x-15-12-507
7 schema:datePublished 2019-04-08
8 schema:datePublishedReg 2019-04-08
9 schema:description INTRODUCTION: This retrospective analysis compares the probability of target attainment (PTA) for ceftriaxone, levofloxacin and ceftaroline fosamil against Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae in a representative patient population with moderate-to-severe community-acquired pneumonia (CAP). METHODS: Published pharmacokinetic (PK) models for levofloxacin and ceftriaxone, and an existing model for ceftaroline, were used with standard dosage regimens for simulating individual PK data with covariates representative of patients with CAP (5000 patients/drug regimen). PTA for clinically relevant pharmacokinetic/pharmacodynamic (PK/PD) targets was calculated from steady state PK profiles for a range of minimum inhibitory concentrations (MICs). Cumulative fractions of response (CFRs) were also calculated using MIC distributions from 2012 to 2017 global surveillance data. RESULTS: Ceftaroline fosamil (600 mg q12 h) achieved > 90% PTA at all exposure targets for each pathogen at European Committee on Antimicrobial Susceptibility Testing (EUCAST)/Clinical and Laboratory Standards Institute (CLSI) susceptibility breakpoints, and CFRs were > 99%. Ceftriaxone, but not levofloxacin, achieved 100% PTA and > 90% CFR against S. pneumoniae. Both levofloxacin and ceftriaxone achieved high PTA and CFR against H. influenzae. Levofloxacin achieved PTAs < 90% at EUCAST/CLSI breakpoints and ceftriaxone achieved PTAs < 90% at MICs up to 2 mg/L against S. aureus; both agents produced generally low CFRs against S. aureus (except levofloxacin against methicillin-sensitive S. aureus), reflecting the lack of activity of these agents against methicillin-resistant S. aureus. CONCLUSION: Ceftaroline fosamil demonstrated higher overall PTA rates than levofloxacin and ceftriaxone, in particular against S. aureus. These results provide insight regarding the potential comparative efficacy of the described antibiotics for moderate-to-severe CAP. FUNDING: Pfizer.
10 schema:genre article
11 schema:inLanguage en
12 schema:isAccessibleForFree true
13 schema:isPartOf N5e892cd2eedf46c49669c2cefe96fa34
14 N9f19e0e3eeb04b40bc250a5502452024
15 sg:journal.1050275
16 schema:keywords CFR
17 CLSI breakpoints
18 Ceftaroline Fosamil Versus Comparators
19 Committee
20 Community-Acquired Pneumonia
21 EUCAST/CLSI breakpoints
22 European Committee
23 Fosamil Versus Comparators
24 Haemophilus influenzae
25 Institute (CLSI) susceptibility breakpoints
26 Laboratory Standards Institute susceptibility breakpoints
27 MIC distribution
28 PK data
29 PK profiles
30 PTA
31 PTA rates
32 PTAS
33 Pfizer
34 Standards Institute (CLSI) susceptibility breakpoints
35 Staphylococcus aureus
36 Streptococcus pneumoniae
37 Versus Comparators
38 activity
39 agents
40 analysis
41 antibiotics
42 antimicrobial susceptibility testing
43 attainment
44 aureus
45 breakpoints
46 ceftaroline
47 ceftaroline fosamil
48 ceftriaxone
49 community-acquired pneumonia
50 comparative efficacy
51 comparator
52 concentration
53 covariates representative
54 cumulative fraction
55 data
56 distribution
57 dosage
58 efficacy
59 exposure targets
60 fosamil
61 fraction
62 global surveillance data
63 higher PTA
64 higher overall PTA rates
65 individual PK data
66 influenzae
67 inhibitory concentration
68 insights
69 lack
70 lack of activity
71 levofloxacin
72 low CFR
73 minimum inhibitory concentration
74 model
75 overall PTA rates
76 pathogens
77 patient population
78 patients
79 pharmacodynamic target
80 pharmacokinetic model
81 pneumonia
82 pneumoniae
83 population
84 potential comparative efficacy
85 probability
86 probability of target
87 profile
88 range
89 rate
90 representative patient population
91 representatives
92 response
93 results
94 retrospective analysis
95 severe community-acquired pneumonia
96 standard dosage
97 state PK profiles
98 steady-state PK profile
99 surveillance data
100 susceptibility breakpoints
101 susceptibility testing
102 target
103 target attainment
104 testing
105 schema:name A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators
106 schema:pagination 185-198
107 schema:productId N1db4fecd628a4f9cb546bef694bd0542
108 N59b8f3c018694174bfed4f4b776fef4e
109 Nab5693b4fedc4e43b20865b6bbc95a7f
110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113301252
111 https://doi.org/10.1007/s40121-019-0243-4
112 schema:sdDatePublished 2021-12-01T19:43
113 schema:sdLicense https://scigraph.springernature.com/explorer/license/
114 schema:sdPublisher Nc6a2b007abe94f3985520b5af94c156f
115 schema:url https://doi.org/10.1007/s40121-019-0243-4
116 sgo:license sg:explorer/license/
117 sgo:sdDataset articles
118 rdf:type schema:ScholarlyArticle
119 N038ae07836674397b0fccbc3efb6fcb2 rdf:first N0414531e00044504854ac7c79be4ec24
120 rdf:rest N0afcbf5803d349b9a5d817ffd32ff018
121 N0414531e00044504854ac7c79be4ec24 schema:affiliation grid-institutes:None
122 schema:familyName Cristinacce
123 schema:givenName Andrew
124 rdf:type schema:Person
125 N0afcbf5803d349b9a5d817ffd32ff018 rdf:first sg:person.013655761054.63
126 rdf:rest N403e696fcf354468b3168e1d354bebfa
127 N1db4fecd628a4f9cb546bef694bd0542 schema:name doi
128 schema:value 10.1007/s40121-019-0243-4
129 rdf:type schema:PropertyValue
130 N3ece334f6af54923a959e14e04c6bb16 rdf:first sg:person.0727526224.27
131 rdf:rest rdf:nil
132 N403e696fcf354468b3168e1d354bebfa rdf:first sg:person.0754245536.93
133 rdf:rest N430264bc7fe54af58dd3b84499ad3e44
134 N430264bc7fe54af58dd3b84499ad3e44 rdf:first sg:person.014247722033.03
135 rdf:rest Nf229c424150d47cb87ec6e628ff1f715
136 N59b8f3c018694174bfed4f4b776fef4e schema:name dimensions_id
137 schema:value pub.1113301252
138 rdf:type schema:PropertyValue
139 N5e892cd2eedf46c49669c2cefe96fa34 schema:issueNumber 2
140 rdf:type schema:PublicationIssue
141 N9f19e0e3eeb04b40bc250a5502452024 schema:volumeNumber 8
142 rdf:type schema:PublicationVolume
143 Nab5693b4fedc4e43b20865b6bbc95a7f schema:name pubmed_id
144 schema:value 30963520
145 rdf:type schema:PropertyValue
146 Nc6a2b007abe94f3985520b5af94c156f schema:name Springer Nature - SN SciGraph project
147 rdf:type schema:Organization
148 Nf229c424150d47cb87ec6e628ff1f715 rdf:first sg:person.01164604234.12
149 rdf:rest N3ece334f6af54923a959e14e04c6bb16
150 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
151 schema:name Medical and Health Sciences
152 rdf:type schema:DefinedTerm
153 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
154 schema:name Clinical Sciences
155 rdf:type schema:DefinedTerm
156 sg:journal.1050275 schema:issn 2193-6382
157 2193-8229
158 schema:name Infectious Diseases and Therapy
159 schema:publisher Springer Nature
160 rdf:type schema:Periodical
161 sg:person.01164604234.12 schema:affiliation grid-institutes:grid.418566.8
162 schema:familyName McFadyen
163 schema:givenName Lynn
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164604234.12
165 rdf:type schema:Person
166 sg:person.013655761054.63 schema:affiliation grid-institutes:None
167 schema:familyName Wright
168 schema:givenName James G.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013655761054.63
170 rdf:type schema:Person
171 sg:person.014247722033.03 schema:affiliation grid-institutes:grid.410513.2
172 schema:familyName Hammond
173 schema:givenName Jennifer
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014247722033.03
175 rdf:type schema:Person
176 sg:person.0727526224.27 schema:affiliation grid-institutes:None
177 schema:familyName Raber
178 schema:givenName Susan
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727526224.27
180 rdf:type schema:Person
181 sg:person.0754245536.93 schema:affiliation grid-institutes:grid.410513.2
182 schema:familyName Stone
183 schema:givenName Gregory G.
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754245536.93
185 rdf:type schema:Person
186 sg:pub.10.1007/s00228-011-1095-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015621133
187 https://doi.org/10.1007/s00228-011-1095-3
188 rdf:type schema:CreativeWork
189 sg:pub.10.1186/1465-9921-14-44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048350425
190 https://doi.org/10.1186/1465-9921-14-44
191 rdf:type schema:CreativeWork
192 sg:pub.10.1186/2047-783x-15-12-507 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004325476
193 https://doi.org/10.1186/2047-783x-15-12-507
194 rdf:type schema:CreativeWork
195 grid-institutes:None schema:alternateName Pfizer, San Diego, CA USA
196 Wright Dose Ltd., Altrincham, Greater Manchester, UK
197 schema:name Pfizer, San Diego, CA USA
198 Wright Dose Ltd., Altrincham, Greater Manchester, UK
199 rdf:type schema:Organization
200 grid-institutes:grid.410513.2 schema:alternateName Pfizer, Collegeville, PA USA
201 Pfizer, Groton, CT USA
202 schema:name Pfizer, Collegeville, PA USA
203 Pfizer, Groton, CT USA
204 rdf:type schema:Organization
205 grid-institutes:grid.418566.8 schema:alternateName Pfizer, Sandwich, Kent, UK
206 schema:name Pfizer, Sandwich, Kent, UK
207 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...